Cumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections: critical appraisal and role in therapy

References

• FoxmanBThe epidemiology of urinary tract infectionNat Rev Urol201071265366021139641
   PubMed Web of Science ®Google Scholar
• RubensteinJNSchaefferAJManaging complicated urinary tract infections: the urologic viewInfect Dis Clin North Am200317233335112848473
   PubMed Web of Science ®Google Scholar
• HermanidesHSHuschlerMESchoutenJAPrinsJMGeerlingsSEDevelopment of quality indicators for the antibiotic treatment of complicated urinary tract infections: a first step to measure and improve careClin Infect Dis200846570371118230045
   PubMed Web of Science ®Google Scholar
• FoxmanBBrownPEpidemiology of urinary tract infections: transmission and risk factors, incidence, and costsInfect Dis Clin North Am200317222724112848468
   PubMed Web of Science ®Google Scholar
• JohnsonCCDefinitions, classification, and clinical presentation of urinary tract infectionsMed Clin North Am19917522412521996031
   PubMed Web of Science ®Google Scholar
• RubinRHShapiroEDAndrioleVTDavisRJStammWEEvaluation of new anti-infective drugs for the treatment of urinary tract infection: Infectious Diseases Society of America and the Food and Drug AdministrationClin Infect Dis195215Suppl 1S216S2271477233
   PubMed Web of Science ®Google Scholar
• NicolleLEAsymptomatic bacteriuria: important or not?N Engl J Med2000343141037103911018172
   PubMed Web of Science ®Google Scholar
• StammWEScientific and clinical challenges in the management of urinary tract infectionsAm J Med2002113Suppl 1A1S4S12113865
   PubMed Web of Science ®Google Scholar
• GaynesREdwardsJRNational nosocomial infections surveillance system. Overview of nosocomial infections caused by gram-negative bacilliClin Infect Dis20054184885416107985
   PubMed Web of Science ®Google Scholar
• GuptaKHootonTMNaberKGInternational clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society of Microbiology and Infectious Diseases201152e103e120
   Google Scholar
• Levofloxacin (Levaquin) [Package insert]Raritan (NJ)Ortho-McNeil-Janssen revised Jan 2011.
   Google Scholar
• LesherGTFroelichEJGruettMDBaileyJHBrundageRP1,8-Naphthyridine derivatives: a new class of chemotherapeutic agentsJ Med Pharm Chem1962911063106514056431
   PubMedGoogle Scholar
• AndrioleVTThe quinolones: past, present, and futureClin Infect Dis200541Suppl 2S113S11915942877
   PubMed Web of Science ®Google Scholar
• MorrisseyIHoshinoKSatoKMechanism of differential activities of ofloxacin enantiomersAntimicrob Agents Chemother1996408177517848843280
   PubMed Web of Science ®Google Scholar
• HawkeyPMMechanisms of quinolone action and microbial responseJ Antimicrob Chemother200351Suppl 1293512702701
   PubMed Web of Science ®Google Scholar
• BlancheFCameronBBernardFXDifferential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerasesAntimicrob Agents Chemother19964012271427209124828
   PubMed Web of Science ®Google Scholar
• EliopolusCTEliopolusGMActivity in vitro of the quinolonesHooperDCRubinsteinEQuinolone Antimicrobial AgentsWashington DCASM Press200391111
   Google Scholar
• O’DonnellJAGeloneSPThe newer fluoroquinolonesInfect Dis Clin North Am200418369171615308282
   PubMed Web of Science ®Google Scholar
• HooperDCStrahilevitzJQuinolonesMandellGLDouglasRGBennettJEMandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases7th edPhiladelphia (PA)Churchill Livingstone, Elsevier2010487510
   Google Scholar
• MaloneRSFishDNAbrahamETeitelbaumIPharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patientsAntimicrob Agents Chemother200145102949295411557500
   PubMed Web of Science ®Google Scholar
• BartonTDFishmanNOWeinerMGLaRosaLALautenbachEHigh rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implicationsInfect Control Hosp Epidemiol2005261939915693415
   PubMed Web of Science ®Google Scholar
• QaqishRPolkREDrug-drug interactionsHooperDCRubinsteinEQuinolone Antimicrobial AgentsWashington DCASM Press2003133146
   Google Scholar
• NorrbySRCentral nervous system toxicityHooperDCRubinsteinEQuinolone Antimicrobial AgentsWashington DCASM Press2003461465
   Google Scholar
• PrestonSLDrusanoGLBermanALPharmacodynamics of levofloxacin: a new paradigm for early clinical trialsJAMA199827921251299440662
   PubMed Web of Science ®Google Scholar
• RybakMJPharmacodynamics: relation to antimicrobial resistanceAm J Med20061196 Suppl 1S37S44 discussionS62S7016735150
   PubMed Web of Science ®Google Scholar
• WispelweyBClinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolonesClin Infect Dis200541Suppl 2S127S13515942879
   PubMed Web of Science ®Google Scholar
• DrusanoGLPrestonSLFowlerCCorradoMWeisingerBKahnJRelationship between fluoroquinolone area under the curve: minimal inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumoniaJ Infect Dis200418991590159715116294
   PubMed Web of Science ®Google Scholar
• FileTMJrNew insights in the treatment by levofloxacinChemotherapy200450Suppl 1222815319551
   PubMed Web of Science ®Google Scholar
• RichardGAChildsSJFowlerCLPitmanWNicolleLECallery-D’AmicoSSafety and efficacy of levofloxacin versus ciprofloxacin in complicated urinary tract infections in adultsPharm Ther199823534540
   Google Scholar
• RichardGAKlimbergINFowlerCLCallery-D’AmicoSKimSSLevofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritisUrology199852151559671870
   PubMed Web of Science ®Google Scholar
• PetersonJKaulSKhashabMFisherACKahnJBA double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritisUrology2008711172218242357
   PubMed Web of Science ®Google Scholar
• KallenAJWelchHGSirovichBECurrent antibiotic therapy for isolated urinary tract infections in womenArch Intern Med2006166663563916567602
   PubMedGoogle Scholar
• WagenlehnerFMWeidnerWNaberKGTherapy for prostatitis, with emphasis on bacterial prostatitisExpert Opin Pharmacother20078111667167417685884
   PubMed Web of Science ®Google Scholar
• BundrickWHeronSPRayPLevofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter studyUrology200362353754112946763
   PubMed Web of Science ®Google Scholar
• BulittaJKinzig-SchippersMNaberKGLimitations in the use of drug cocktails to compare the pharmacokinetics of drugs: ciprofloxacin versus levofloxacin40th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 17–20, 2000Toronto, Canada
   Google Scholar
• NickelJCDowneyJClarkJLevofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trialUrology200362461461714550427
   PubMed Web of Science ®Google Scholar
• NickelJCChronic prostatitis: an infectious disease?Infect Urol2000133138
   Google Scholar
• McGregorJCAllenGPBeardenDTLevofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritisTher Clin Risk Manag20084584385319209267
   PubMedGoogle Scholar
• BolonMKThe newer fluoroquinolonesInfect Dis Clin North Am20092341027105119909896
   PubMed Web of Science ®Google Scholar
• JacobyGAMechanisms of resistance to quinolonesClin Infect Dis200541Suppl 2S120S12615942878
   PubMed Web of Science ®Google Scholar
• KriengkauykiatJPorterELomovskayaOWong-BeringerAUse of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosaAntimicrob Agents Chemother200549256557015673734
   PubMed Web of Science ®Google Scholar
• PoirelLCattoirVNordmannPIs plasmid-mediated quinolone resistance a clinically significant problem?Clin Microbiol Infect200814429529718190576
   PubMed Web of Science ®Google Scholar
• GuptaKHootonTMWobbeCLStammWEThe prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young womenInt J Antimicrob Agents1999113–430530810394988
   PubMed Web of Science ®Google Scholar
• LautenbachEStromBBilkerWBPatelJBEdelsteinPHFishmanNOEpidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniaeClin Infect Dis20013381288129411565067
   PubMed Web of Science ®Google Scholar
• JonesRNKirbyJTRhombergPRComparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillanceDiag Microbiol Infect Dis2008612203213
   Web of Science ®Google Scholar
• ZhanelGGHisanagaTLLaingNMAntibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)Int J Antimicrob Agents200627646847516713191
   PubMed Web of Science ®Google Scholar
• DragoLNicolaLMattinaRDe VecchiEIn vitro selection of resistance in Escherichia coli and Klebsiella spp at in vivo fluoroquinolone concentrationsBMC Microbiol20101011920409341
   PubMed Web of Science ®Google Scholar
• OwensRCJrAmbrosePGAntimicrobial safety: focus on fluoroquinolonesClin Infect Dis200541Suppl 2S144S15715942881
   PubMed Web of Science ®Google Scholar
• MehlhornAJBrownDASafety concerns with fluoroquinolonesAnn Pharmacother200741111859186617911203
   PubMed Web of Science ®Google Scholar
• TanneJHFDA adds “black box” warning label to fluoroquinolone antibioticsBMJ2008337a81618632714
   PubMed Web of Science ®Google Scholar
• KhaliqYZhanelGGFluoroquinolone-associated tendinopathy: a critical review of the literatureClin Infect Dis200336111404141012766835
   PubMed Web of Science ®Google Scholar
• MorganrothJDimarcoJPAnzuetoANiedermanMSChoudhriSfor CAPRIE Study GroupA randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumoniaChest200512853398340616304291
   PubMed Web of Science ®Google Scholar
• LewisRJMohrJF3rdDysglycaemias and fluoroquinolonesDrug Saf200831428329218366239
   PubMed Web of Science ®Google Scholar
• NicolleLEBradleySColganRInfectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adultsClin Infect Dis200540564365415714408
   PubMed Web of Science ®Google Scholar